GLOW Quick Reference (70 mg vial)
Research context: mechanisms, human and preclinical evidence, limitations and precautions are in How this works and References. The calculator (Spanish) converts any other volume.
GLOW Dosage Chart (70 mg vial)
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard Approach (3 mL = ~23.33 mg/mL)
| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Weeks 1–4 | 2.33 mg (2330 mcg) | 10 units (0.10 mL) |
Frequency: Once daily, subcutaneously, at a consistent time.
Reconstitution Steps
- Draw 3 mL of bacteriostatic water with a sterile syringe.1
- Inject slowly down the vial wall; avoid shaking to prevent foaming.2
- Gently swirl or roll until fully dissolved (clear solution).3
- Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.4
Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
U-100 Conversion Table (3 mL = 23.33 mg/mL)
| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 466.667 mcg | 150 injections |
| 5 | 0.05 mL | 1.16667 mg (1167 mcg) | 60 injections |
| 10 | 0.10 mL | 2.33333 mg (2333 mcg) | 30 injections |
| 20 | 0.20 mL | 4.66667 mg (4667 mcg) | 15 injections |
| 30 | 0.30 mL | 7 mg (7000 mcg) | 10 injections |
| 50 | 0.50 mL | 11.6667 mg (11667 mcg) | 6 injections |
| 100 | 1.00 mL | 23.3333 mg (23333 mcg) | 3 injections |
This section describes which dose a study or reference source used and what it measured. It is not a recommendation or an administration schedule. A trial dose belongs to its population, duration and supervision and does not transfer to anyone outside that context.
Supplies Needed
Straightforward 12- and 24-week planning for a 70 mg vial at 23.33 mg/mL.
GLOW vials (70 mg each)
- Standard Approach, 12 weeks: Minimum 3 vials (195.72 mg required).
- Standard Approach, 24 weeks: Minimum 6 vials (391.44 mg required).
U-100 syringes (1 mL)
- Standard Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard Approach, 24 weeks: 168 new syringes for 168 injections.
Bacteriostatic water
- Standard Approach, 12 weeks: 9 mL total (3 mL per vial) → 3 × 3 mL vials.
- Standard Approach, 24 weeks: 18 mL total (3 mL per vial) → 6 × 3 mL vials.
Alcohol swabs
- Standard Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.
Sharps container: one appropriately sized. Stability planning: totals are minimum arithmetic quantities; follow the product documentation for sterility, storage, handling loss and discard timing.
GLOW 70mgView in store
Bacteriostatic water 3 mLView in storeStore links may earn a commission. A supplier page is not scientific evidence or proof of suitability for human use.
GLOW Vial and Research Context
- Reconstitute: add 3 mL of bacteriostatic water to produce 23.33 mg/mL.
- Frequency in the source: once daily, subcutaneously.
- Described range: schedules run from 2.33 mg (2330 mcg) to 2.33 mg (2330 mcg) per injection.
- Easy measuring: 1 U-100 unit = 0.01 mL = 233 mcg.
- Vial size: the 70 mg label is total nominal content, not a per-injection amount.
- Vial coverage: at 2.33 mg (2330 mcg) per injection one vial supplies 30 injections; at 2.33 mg (2330 mcg) it supplies 30. These are mass calculations, not storage periods.
Protocol Overview
Quick reference for the schedules shared by the cited literature.
- Frequency: once daily.
- Concentration: 70 mg in 3 mL = 23.33 mg/mL.
- Unit conversion: 1 U-100 unit = 233 mcg.
Dosing Schedule
The tables keep each approach separate.
- Standard Approach: 2.33 mg (2330 mcg), in phases (once daily).
- Measurement: use the units and mL shown beside each amount.
Storage Instructions
- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.
More detail in the storage guide (Spanish).
Important Notes
- Research only: the referenced compounds are sold for laboratory research. Nothing here is medical advice or an administration schedule.
- Above 100 units: a 1 mL U-100 syringe cannot hold them; split across syringes or reconstitute with less volume.
- Accuracy: concentration depends on the actual volume added; measure the diluent with a syringe, not by eye.
- Verification: confirm vial contents against the batch certificate of analysis before calculating.
How This Works
GLOW is a research tri-peptide blend in a single 70 mg lyophilized vial that combines two tissue-repair peptides (BPC-157 and TB-500) with a copper tripeptide for dermal remodeling (GHK-Cu). The literature describes complementary pathways of angiogenesis, cell migration, and extracellular matrix synthesis in experimental models.
Blend composition (70 mg lyophilized per vial):
- BPC-157 (10 mg): pentadecapeptide derived from a gastric juice protective sequence. Preclinical literature documents upregulation of VEGFR2 (angiogenesis) and repair of tendon, ligament, and mucosa in murine models. Vasireddi N et al., Am J Sports Med 2025 (PMID 40756949) review 36 studies on the modulation of tissue repair pathways.
- TB-500 (10 mg): Synthetic fragment (LKKTETQ) of Thymosin Beta-4. Literature documents cell migration, angiogenesis via AC-SDKP, and cytokine modulation. Crockford D et al., Ann N Y Acad Sci 2010 (PMID 20955331) y Sosne G et al., Exp Eye Res 2002 (PMID 11819014) in healing models.
- GHK-Cu (50 mg): Gly-His-Lys tripeptide complexed with copper (II). Literature describes synthesis of type I/III collagen, extracellular matrix modulation, antioxidant activity, and suppression of TGF-β1. Pickart L, Margolina A, Int J Mol Sci 2018 (PMID 30041448) Review the dermatologic remodeling.
Research Applications
- BPC-157 (10 mg): pentadecapeptide derived from a gastric juice protective sequence. Preclinical literature documents upregulation of VEGFR2 (angiogenesis) and repair of tendon, ligament, and mucosa in murine models. Vasireddi N et al., Am J Sports Med 2025 (PMID 40756949) review 36 studies on the modulation of tissue repair pathways.
- TB-500 (10 mg): Synthetic fragment (LKKTETQ) of Thymosin Beta-4. Literature documents cell migration, angiogenesis via AC-SDKP, and cytokine modulation. Crockford D et al., Ann N Y Acad Sci 2010 (PMID 20955331) y Sosne G et al., Exp Eye Res 2002 (PMID 11819014) in healing models.
- GHK-Cu (50 mg): Gly-His-Lys tripeptide complexed with copper (II). Literature describes synthesis of type I/III collagen, extracellular matrix modulation, antioxidant activity, and suppression of TGF-β1. Pickart L, Margolina A, Int J Mol Sci 2018 (PMID 30041448) Review the dermatologic remodeling.
Research material only. No FDA-approved human use. Information is provided for educational and scientific literature reference purposes.
Injection Technique in Research
- Route in the studies: subcutaneous, in abdominal or thigh adipose tissue, rotating the site.
- Syringe: 1 mL U-100 (100 units); read in units, not mL.
- Asepsis: alcohol swab on the stopper and the site; a new syringe per injection.
- Drawing: purge air, draw the units from the chart and verify before withdrawing the needle from the vial.
Full guide: U-100 syringes and reading units (Spanish).
Research Note
All content on this page is technical and educational. It describes how a vial is reconstituted, how a syringe is read and which amounts the cited sources describe. It does not replace the supervision of a qualified researcher or the judgment of a health professional, and it is not intended to diagnose, treat, cure or prevent any disease.